7AIY

Crystal structure of human butyrylcholinesterase in complex with 2-{1-[4-(12-Amino-3-chloro-6,7,10,11-tetrahydro-7,11-methanocycloocta[b]quinolin-9-yl)butyl]-1H-1,2,3-triazol-4-yl}-N-[4-hydroxy-3-methoxybenzyl]acetamide

Summary for 7AIY

• Entry DOI: 10.2210/pdb7aiy/pdb
• Descriptor: Cholinesterase, 2-{1-[4-(12-Amino-3-chloro-6,7,10,11-tetrahydro-7,11-methanocycloocta[b]quinolin-9-yl)butyl]-1H-1,2,3-triazol-4-yl}-N-[4-hydroxy-3-methoxybenzyl]acetamide (2 entities in total)
• Functional Keywords: human butyrylcholinesterase, ad, alzheimer disease, hydrolase
• Biological source: Homo sapiens (Human)
• Total number of polymer chains: 2
• Total formula weight: 137566.58

Authors

Coquelle, N.,Colletier, J.P. (deposition date: 2020-09-28, release date: 2021-10-06, Last modification date: 2024-11-13)

Primary citation

Viayna, E.,Coquelle, N.,Cieslikiewicz-Bouet, M.,Cisternas, P.,Oliva, C.A.,Sanchez-Lopez, E.,Ettcheto, M.,Bartolini, M.,De Simone, A.,Ricchini, M.,Rendina, M.,Pons, M.,Firuzi, O.,Perez, B.,Saso, L.,Andrisano, V.,Nachon, F.,Brazzolotto, X.,Garcia, M.L.,Camins, A.,Silman, I.,Jean, L.,Inestrosa, N.C.,Colletier, J.P.,Renard, P.Y.,Munoz-Torrero, D.
Discovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP/PS1 Mice.
J.Med.Chem., 64:812-839, 2021

PubMed Abstract: The combination of the scaffolds of the cholinesterase inhibitor huprine Y and the antioxidant capsaicin results in compounds with nanomolar potencies toward human acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) that retain or improve the antioxidant properties of capsaicin. Crystal structures of their complexes with AChE and BChE revealed the molecular basis for their high potency. Brain penetration was confirmed by biodistribution studies in C57BL6 mice, with one compound () displaying better brain/plasma ratio than donepezil. Chronic treatment of 10 month-old APP/PS1 mice with (2 mg/kg, i.p., 3 times per week, 4 weeks) rescued learning and memory impairments, as measured by three different behavioral tests, delayed the Alzheimer-like pathology progression, as suggested by a significantly reduced Aβ42/Aβ40 ratio in the hippocampus, improved basal synaptic efficacy, and significantly reduced hippocampal oxidative stress and neuroinflammation. Compound emerges as an interesting anti-Alzheimer lead with beneficial effects on cognitive symptoms and on some underlying disease mechanisms.

PubMed: 33356266
DOI: 10.1021/acs.jmedchem.0c01775

Experimental method

X-RAY DIFFRACTION (2.937 Å)